JPRN-jRCT2080220444已完成3 期
Phase III study of FTB-8127 in patients with post-herpetic neuralgia (A placebo-controlled, multicenter, double-blind, parallel-group study)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients who have been over 3 months after the onset of herpes zoster
- •(2) Patients aged 20 years or older at the time of informed consent
- •(3) Patients providing written informed consent about participation in this clinical trial
- •(4) Hospitalized patients and outpatients. In outpatients, who may be able to visit once a week
- •(5) Patients who have been treated with drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics adjuvants for PHN within 2 weeks before the start of the pre-observation period
- •(6) In case of undergoing nerve block therapy, patients who are treated regularly (once a week or once every 2 weeks) or may be able to be treated regularly for 2 weeks before the start of the pre-observation period
- •(7) Out of 7 days of the pre-observation period (measured three times a day in the morning, daytime, and night), patients getting a maximum daily VAS pain score of 40 or more and having been gotten a maximum daily pain degree (Verbal Rating Scale: VRS) of moderate to severe for 4 days or more respectively
排除标准
- •(1) Patients with head disorders or brain lesions who are suspected of obnubilation
- •(2) Patients with a history or complication of elevated intracranial pressure
- •(3) Patients with consciousness disorders (e.g., unable to speak) or convulsions (e.g., status epilepticus)
- •(4) Patients with serious respiratory depression and pulmonary function impairment
- •(5) Patients with a history or complication of malignancies
- •(6) Patients with a history of hypersensitivity to opioid analgesics
- •(7) Patients who used opioid analgesics within 4 weeks before the start of the pre-observation period
- •(8) Patients who are drug addicts or drug abusers or who have a history of drug dependence
- •(9) Patients who are pregnant, lactating, or who have the possibility of pregnancy, or who wish to become pregnant during the clinical trial period
- •(10) Patients who participated in another clinical trial within 90 days before the start of the pre-observation period
- •(11) Patients with AST (GOT), ALT (GPT) of 100IU/L or more, total bilirubin of 3.0mg/dL or more, and serum creatinine of 2.0mg/dL or more on laboratory data up to 4 weeks before the start of the pre-observation period
- •(12) Patients who started the following pain relief treatments during the pre-observation period
- •1) Opioid analgesics, non-opioid analgesics, analgesics adjuvants, nerve block
- •2) Surgery that may affect pain assessment
- •3) Prohibited drugs (barbiturate derivatives, MAO inhibitors, CYP3A4 inhibitors)
- •(13) Patients who are judged to be inadequate by the investigator, etc
研究者
相似试验
未知
3 期
Phase3 study of T-1220 in the patients with bacterial infectious disease-Open label, multi-center studySepsis, Acute bronchitis, Pneumonia, Lung abscess, Pyothorax, Secondarinfection of chronic respiratory disease, Cystitis, Pyelonephritis, Cholecystitis, Cholangitis, Bartholinitis, Intrauterine infection, Uterine adnexitis, Parametritis, Purulent meningitisyJPRN-jRCT2080221672Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
招募中
3 期
A phase 3 study of S-812217 in patients with major depressive disorderdepressionJPRN-jRCT2031210577agata Tsutae400
未知
2 期
Phase II study of ET-743 in patients with translocation-related sarcomasJPRN-jRCT2080221808Taiho Pharmaceutical Co., Ltd.74
进行中（未招募）
1 期
A Study of FT-2102 in Patients with Advanced Solid Tumors and GliomasAdvanced Solid Tumors and Gliomas with an IDH1 MutationMedDRA version: 20.0Level: PTClassification code 10018338Term: GliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073073Term: Hepatobiliary cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001796-21-ESFORMA Therapeutics, Inc.200
进行中（未招募）
1 期
A Study of FT-2102 in Patients with Advanced Solid Tumors and GliomasAdvanced Solid Tumors and Gliomas with an IDH1 MutationMedDRA version: 20.0Level: PTClassification code 10018338Term: GliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073073Term: Hepatobiliary cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001796-21-GBForma Therapeutics, Inc.200